Clinical trials: Chronic Constipation
Constipation
Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain
The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects with chronic pain, which is not due to…
- Trial name
- NCT00547586
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 41 sites in United States
- Volunteers
- 122 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-induced Constipation
A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy
The purpose of this study is to determine efficacy and safety of naldemedine for the treatment of opioid-induced constipation in adults with non-malignant chronic pain receiving opioid therapy for ≥ 3 months.
- Trial name
- NCT01443403
- Testing
- Naldemedine
- Where
- 49 sites in United States
- Volunteers
- 244 people
- Sponsor
- Shionogi
Constipation
Probiotics for Alleviating Chronic Constipation in Adults
To investigate the clinical effects of probiotics in relieving intestinal motility and chronic constipation through regulating gut microbiota.
- Trial name
- NCT07152795
- Testing
- Probiotic
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Chronic Constipation
A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation
The objective of this study is to investigate dose-responses of efficacy and safety of ASP0456 in patients with chronic constipation (diagnosed by Rome III criteria of functional constipation (FC), not including constipation due…
- Trial name
- NCT02425722
- Testing
- ASP0456
- Where
- 50 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Astellas Pharma Inc
Constipation - Functional
Clinical Trial Assessing the Efficacy and Safety of Hépar® in Chronic Constipation
The study objectives are to evaluate the efficacy and safety of a 2-week daily intake of 1L Hépar® natural mineral water rich in magnesium sulphate compared to a control natural mineral water in the treatment of the constipation…
- Trial name
- HEP02 (NCT03348007)
- Testing
- Taking two kinds of mineral water
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Quanta Medical
Chronic Idiopathic Constipation
Lubiprostone for Treatment of Chronic Idiopathic Constipation
The purpose of this study was to evaluate the efficacy and safety of oral administration of lubiprostone 24 μg twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02695719
- Testing
- Lubiprostone
- Where
- 5 sites in South Korea
- Volunteers
- 156 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation
Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
- Trial name
- NCT01827592
- Testing
- Elobixibat 10 mg, Elobixibat 5 mg
- Where
- 94 sites in United States, Belgium and 8 more
- Volunteers
- 376 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Constipation
Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)
The purpose of this study is to evaluate the safety and efficacy of KWA-0711 in Chronic Constipation (CC) patients.
- Trial name
- NCT02343978
- Testing
- KWA-0711
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Constipation
An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation
Tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-HT) agonists. Activation of 5-HT4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn…
- Trial name
- NCT00139568
- Testing
- Tegaserod
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- Novartis
Opioid-Induced Constipation
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been…
- Trial name
- NCT02270983
- Testing
- Linaclotide 145 micrograms, Linaclotide 290 micrograms
- Where
- 77 sites in United States
- Volunteers
- 254 people
- Sponsor
- Forest Laboratories
Chronic Idiopathic Constipation
Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation
To evaluate the pharmacodynamics and tolerability of a liquid formulation of lubiprostone, as compared to matching placebo, when administered orally to subjects with chronic idiopathic constipation.
- Trial name
- NCT01993875
- Testing
- Lubiprostone
- Where
- 11 sites in United States
- Volunteers
- 164 people
- Sponsor
- Mallinckrodt
Chronic Pain, Opioid Induced Constipation
Naloxone SR Capsules in Patients With Opioid Induced Constipation
For many patients taking opioids for pain relief one of the most distressing side effects is constipation. Naloxone is effective in the reversal of the effects of opioids and is used following opioid overdose.
- Trial name
- NCT00984334
- Testing
- Naloxone SR 5 mg capsules, Naloxone SR 10 mg capsules, Naloxone SR 20mg capsules
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 40 people
- Sponsor
- S.L.A. Pharma AG
Constipation
Lubiprostone for Chronic Idiopathic Constipation Treatment
The purpose of this study is to evaluate the efficacy and safety of oral administration of 24 ug of lubiprostone twice daily (BID) for 4 weeks in participants with chronic idiopathic constipation (CIC) compared with placebo.
- Trial name
- NCT02729909
- Testing
- Lubiprostone
- Where
- 10 sites in Mexico
- Volunteers
- 211 people
- Sponsor
- Takeda
Chronic Idiopathic Constipation
A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
The purpose of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus lubiprostone in constipated adults.
- Trial name
- NCT02481947
- Testing
- BLI400 Laxative, Lubiprostone
- Where
- 50 sites in United States
- Volunteers
- 459 people
- Sponsor
- Braintree Laboratories
Opioid-induced Constipation
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.
- Trial name
- NCT01965158
- Testing
- Naldemedine
- Where
- 65 sites in United States, Austria and 5 more
- Volunteers
- 547 people
- Sponsor
- Shionogi
Constipation
Prucalopride in Patients With Chronic Idiopathic Constipation
The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of chronic idiopathic constipation. Hypothesis: Prucalopride given at a dose of 1 mg o.d.
- Trial name
- NCT00575614
- Testing
- prucalopride
- Volunteers
- 87 people
- Sponsor
- Movetis
Chronic Idiopathic Constipation
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT01919697
- Testing
- Plecanatide
- Where
- 220 sites in United States, Canada
- Volunteers
- 2,370 people
- Sponsor
- Bausch Health Americas, Inc.